Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 10/20 | 0.61 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.61 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.61 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.61 |
| ▸ | ITGAL | P20701 | 1/20 | 0.61 |
| ▸ | FPR2 | P25090 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.47 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.47 |
| ▸ | CCKAR | P32238 | 1/20 | 0.47 |
| ▸ | CCKBR | P32239 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927344 | 0.93 | ITGB2 (0.62) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL28856403 | 0.84 | ITGB2 (0.57) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL6618300 | 0.83 | ITGB1 (0.54) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL24008866 | 0.82 | CAPN1 (0.54) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL29961542 | 0.82 | CAPN1 (0.54) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL15145328 | 0.79 | FPR2 (0.55) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL3974290 | 0.78 | ITGB1 (0.52) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL3974284 | 0.78 | ITGB1 (0.52) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL3975886 | 0.77 | HDAC1 (0.53) | ITGB1ITGA4HPGD | |
| SCHEMBL3975891 | 0.77 | HDAC1 (0.53) | ITGB1ITGA4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| CN-1703395-A | Aryl and heteroaryl compounds and methods of modulating blood coagulation | TRANSTECH PHARMA INC (US) | 2005-11-30 | — | — | CN | disclosed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | ITGB1 139/4885ITGA4 171/4885ITGB2 188/4885 |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | ITGB1 240/4885ITGA4 312/4885ITGB2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.